ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).

Darren R. Feldman,Marion Feuilly,Jie Meng,Johanna Lister,Florence Marteau,Michael J. Morris,Daniel J. George,Toni K. Choueiri

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).

2018

Darren R. Feldman
Marion Feuilly
Jie Meng
Johanna Lister
Florence Marteau
Michael J. Morris
Daniel J. George
Toni K. Choueiri

e18690Background: CABOSUN, a randomized and open-label phase II trial, demonstrated significant improvement in progression-free survival (PFS) with cabozantinib versus sunitinib in the first-line t...

Keywords:

Physical therapy
Alliance
ECOG Score
Oncology
Renal cell carcinoma
Proxy (climate)
Quality of life
Internal medicine
Medicine
intermediate risk
Cabozantinib
in patient
health related quality of life
Sunitinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations